The societal burden of chronic liver diseases: Results from the COME study

BMJ Open Gastroenterology

Volumn 2, Issue 1, 2015, Pages

  Scalone, Luciana ^a,b   Fagiuoli, Stefano ^c   Ciampichini, Roberta ^a,b   Gardini, Ivan ^d   Bruno, Raffaele ^c,e,f   Pasulo, Luisa ^c   Lucà, Maria Grazia ^c   Fusco, Francesco ^b,g   Gaeta, Laura ^h   Del Prete, Anna ^h   Cesana, Giancarlo ^a   Mantovani, Lorenzo Giovanni ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Fondazione Charta   (Italy)

^c PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^d Organizzazione di pazienti EpaC ONLUS   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g SCUOLA SUPERIORE SANT ANNA   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTIVIRUS AGENT; NUTRITION SUPPLEMENT; VITAMIN;

ABSENTEEISM; ADULT; AGED; ALTERNATIVE MEDICINE; ANTIVIRAL THERAPY; ARTICLE; BENCHMARKING; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HERBAL MEDICINE; HOMEOPATHY; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY;

EID: 84954519383     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2014-000025     Document Type: Article

References (33)

1. European Centre for Disease Prevention and Control. Hepatitis B and Cin the EU neighborhood: prevalence, burden of disease and screening policies. 2010.
2. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009;150:104-10.
3. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
4. NIH Consensus Statement on Management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
5. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127: S35-S50.
6. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A metaanalysis and meta-regression. Hepatology 2008;48:418-31.
7. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(Suppl 1):1-16.
8. Ong SC, Mak B, Aung MO, et al. Health-related quality of life in chronic hepatitis B patients. Hepatology 2008;47:1108-17.
9. Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early-And late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012;27:149-57.
10. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: A survey in 5 countries. BMC Gastroenterology 2013;13:16.
11. Federico CA, Hsu PC, Krajden M, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int 2012;32:815-25.
12. Khoury AC, Klimack WK, Wallace C, et al. Economic burden of hepatitis C-Associated diseases in the United States. J Viral Hepat 2012;19:153-60.
13. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) 2011;7:661-71.
14. McCombs JS, Yuan Y, Shin J, et al. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther 2011;33:1268-80.
15. Su J, Brook RA, Kleinman NL, et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010;52:436-42.
16. Yang BM, Kim DJ, Byun KS, et al. The societal burden of HBV-related disease: South Korea. Dig Dis Sci 2010;55:784-93.
17. Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat 2009;16:53-63.
18. Gutteling JJ, de Man RA, Busschbach JJ, et al. Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007;65:227-34.
19. Grant WC, Jhaveri RR, McHutchison JG, et al. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005;42:1406-13.
20. Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: A cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70.
21. World Medical Association (WMA) Declaration of Helsinki. Adopted by the 18thWorld Medical Assembly, Helsinki, Finland, June 1964, amended by the 29thWorld Medical Assembly, Tokyo, Japan, October 1975, the 35thWorld Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989.
22. Prezzi dei farmaci. http://farmaco.agenziafarmaco.it/index.php, visited in January 2011.
23. Tariffari regionali delle prestazioni di assistenza ospedaliera provided under the hospitalization and day-hospital. http://www.agenas.it/monitoraggio-costi.html, visited in July 2011.
24. Prestazioni specialistiche ambulatoriali-confronto tra le tariffe nazionali ex DM 1996 e le tariffe regionali massime relative all'anno 2008. http://www.agenas.it/monitoraggio-costi-Tariffe/monitoraggio-costi-Tariffe-prestazioni.htm visited in January 2011.
25. Rabin R, de Charro F. EQ-5D: A measure of health status from the Euro QoL Group. Ann Med 2001;33:337-43.
26. Scalone L, Ciampichini R, Fagiuoli S, et al. Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic liver diseases. Qual Life Res 2013;22:1707-16.
27. Scalone L, Cortesi PA, Ciampichini R. Italian population-based values of EQ-5D health states. Value Health 2013;16:814-22.
28. van Hout B, Janssen MF, Feng YS, et al. Value sets for the EQ-5D-5L: A mapping approach. Value Health 2012;15:708-15.
29. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: A systematic review. Med Decis Making 2008;28:582-92.
30. Orr JG, Homer T, Ternent L, et al. Health related quality of life in people with advanced chronic liver disease. J Hepatol 2014;61:1158-65.
31. Krabbe PF, Devlin NJ, Stolk EA, et al. Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5 L health-state values. Med Care 2014;52:935-43.
32. Oppe M, Devlin NJ, van Hout B, et al. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health 2014;17:445-53.
33. Devlin NJ, Krabbe PF. The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ 2013;14(Suppl 1):S1-S3.